Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 1/20 | 0.59 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TDP2 | O95551 | 4/20 | 0.48 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | APAF1 | O14727 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041817 | 0.96 | CTSL (0.53) | PTPRCCTSLCTSSPTPN13ALDH1A1 | |
| SCHEMBL6607479 | 0.88 | MAOB (0.50) | PTPRCCTSLCTSSPTPN13ALDH1A1 | |
| SCHEMBL3786936 | 0.83 | PTPRC (0.52) | PTPRCCTSLCTSSPTPN13ALDH1A1 | |
| SCHEMBL30777768 | 0.74 | PTPRC (1.00) | PTPRCCTSLCTSSPTPN13ALDH1A1 | |
| SCHEMBL4048788 | 0.74 | PTPRC (1.00) | PTPRCCTSLCTSSPTPN13ALDH1A1 | |
| SCHEMBL18347632 | 0.70 | ALDH1A1 (0.87) | PTPRCCTSLCTSSPTPN13ALDH1A1 | |
| SCHEMBL69772 | 0.70 | PTPRC (0.91) | PTPRCCTSLCTSSPTPN13ALDH1A1 | |
| SCHEMBL30799541 | 0.70 | PTPRC (0.91) | PTPRCCTSLCTSSPTPN13ALDH1A1 | |
| SCHEMBL4066187 | 0.68 | TDP1 (0.42) | ALDH1A1TDP2PLCG1CES1NSD2 | |
| 9,10-Phenanthrenequinone SCHEMBL43050 | 0.68 | MEN1 (1.00) | PTPRCCTSLCTSSPTPN13ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446390-A2 | PHOTOCHROMIC OXAZINE COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2004-08-18 | — | — | EP | claimed |
| US-6686466-B2 | HEATING AN ISOCYANATE DERIVATIVE WITH A SYMMETRIC QUINONE IN PRESENCE OF TRIPHENYLARSEN OXIDE CATALYST TO FORM 2,2-DIPHENYL-PHENANTHRO (9,10)-2H-(1,4)-OXAZINE DERIVATIVES | JOHNSON & JOHNSON VISION CARE, INC. | 2004-02-03 | — | — | US | claimed |
| US-20030125552-A1 | Photochromic oxazine compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2003-07-03 | — | — | US | claimed |
| WO-2003042195-A2 | PHOTOCHROMIC OXAZINE COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2003-05-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125552-A1 | Photochromic oxazine compounds and methods for their manufacture | PPOX, DHPS, ALDH1A2 | PTPRC 971/4885CTSL 4884/4885CTSS 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.